switching between glp 1 agonists chart GLP‐1 receptor in clinical practice: Expert consensus and practical guidance - Jain - 2021 - International Journal of Clinical Practice Schematic illustration of monoagonists, dual

Lilly showed in recently announced clinical trial results that patients who switched to orforglipron after losing weight on either Wegovy or Zepbound regained less weight than participants who switched to a placebo

However, this advantage is contingent upon rigorous demonstration of exposureresponse relationships and the avoidance of overgeneralized claims based solely on preclinical data

Still, it may be relevant to perform pilot studies to address whether the therapy will benefit selected HFrEF cohorts with obesity.

The translational chain from metabolic benefit to reproductive success remains a critical gap that high-quality research must address

Uddin GM, Karwi QG, Pherwani S, Gopal K, Wagg CS, Biswas D, et al

Compounded semaglutide Compounded semaglutide is custom-made by licensed compounding pharmacies to accommodate a patients specific needs when commercially available drugs arent an option